entertainment -WSS

entertainment

author：knowledge 2025-09-02 11:48:31 - browse：99876

Lung cancer under microscope — coverage from STAT — Lung cancer Adobe

CHICAGO — Delfi Diagnostics, a company seeking to develop liquid biopsy tests to help screen for lung cancer, published a scientific paper on Monday describing key aspects of the test and unveiled the design of a key clinical trial.

Delfi also announced that the Merck Global Health Innovation Fund, the VC arm of the drug giant, has made an investment of an undisclosed amount in the company.

Unlike Grail, a unit of Illumina, or Exact Sciences, which seeks to develop a blood test that can be used to screen for multiple types of cancer, Delfi is focusing on a single disease — lung cancer — in which the utility of screening with existing technology is not in dispute. Using low-dose CT scans to detect lung cancer is considered an established technology for people at higher risk of lung cancer. However, far too few people get screened.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Apple is now the first public company to be valued at $3 trillion
Next article： Teladoc has a new CEO, but challenges remain the same

focus

WSS

'Essentially witchcraft:' A former naturopath takes on the field

Moderna says combo Covid

New report analyzes digital physical therapy solutions' effectiveness

Lilly's Alzheimer's drug donanemab backed by FDA advisers

Lilly's Alzheimer's drug donanemab backed by FDA advisers

STAT Virtual Event: ASCO Recap, Live!

knowledge

entertainment

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

FDA approval of Sarepta Duchenne genetic therapy gives me hope

'Essentially witchcraft:' A former naturopath takes on the field

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Cigna wins case to block Amy Bricker's move to CVS

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Report captures long Covid’s disabling effects and policy challenges

Medical leaders decry Supreme Court decision on affirmative action

Cheap, fast test for Zika and dengue could cost just $1

Hepatitis C has a cure — but many Americans still lack access to it

FDA reviewers ask if approval of Lilly’s Alzheimer’s drug should be restricted

hotspot

NIH tests clinical research in primary care with $30 million program

Moderna says combo Covid

Readers discuss the intersection of pregnancy and addiction

The system is set up to fail children with medical complexity

Heat wave can put hearts into ‘oxygen debt,' lab experiment shows

Heat wave can put hearts into ‘oxygen debt,' lab experiment shows

focus

Wikipedia

focus

Wikipedia